Jun 12, 2021
By Jeremy Logan
Almost three dozen Canadian pharmaceutical companies made a direct appeal to Prime Minister Justin Trudeau last month to delay new drug pricing regulations for a third time.
The regulations will make major changes to how the Patented Medicine Pricing Review Board ensures medications still under patent protection are priced fairly.
They adjust which countries are used for comparison price purposes, introduce new economic factors to guide pricing and allow the review board access to negotiated price rebates drug companies make with provincial governments.
The companies want more time, and less pandemic distraction, to try and make their case to the Liberals that the regulations will get in the way of Trudeau’s promise to rebuild Canada’s life sciences sector.
The review board, however, says in documents obtained by the Conservatives through an access to information request, that drug companies are waging a campaign of disinformation and fear, threatening Canadians they won’t sell innovative medicines in Canada if the regulations go ahead.
A spokeswoman for Health Minister Patty Hajdu says the reforms were delayed before only to ensure industry had time to adjust and are set to be implemented July 1st.